The German Federal Joint Committee's (G-BA) decision of April 16, 2026, to classify the additional benefit of Donanemab as „not substantiated“ does not surprise the digiDEM project management. The G-BA had already reached this conclusion for Lecanemab in February 2026 of this year. Now it appears that the second drug with a similar mechanism of action also cannot...
The decision by the Joint Federal Committee (G-BA) of February 19, 2026, to classify the additional benefit of Lecanemab as ‚not proven‘ confirms the skepticism of the digiDEM project management regarding the clinical relevance of this therapy. While the only study available so far on Lecanemab shows a statistically significant difference between the drug and a placebo at the end of the study...
Since 1994, German long-term care insurance has covered some of the risks associated with requiring care. A comprehensive reform in 2016 fundamentally changed the definition of requiring care: Since then, in addition to physical limitations, mental and psychological impairments of independence have been equally considered when assessing care needs. This is particularly relevant for people with dementia and their...
In the second part of our new special newsletter, SCHLAGLICHT – New Dementia Medications, Jana Rühl, a research associate at digiDEM Bavaria, discusses the publication by the research team led by Professor Sören Mattke from the University of Southern California. Today, we address the question of whether healthcare systems can even cope with the diagnostic requirements...
SPOTLIGHT – New Medications for Dementia – this is the name of our new series on new active ingredients for the treatment of Alzheimer's disease. We want to shed „spotlight“ on the multifaceted topic of „New Dementia Medications and Challenges for Everyday Care.“ These new medications are intended for people in the early stages of the disease or in the mild phase...
